Squawk on the Street Cramer's Morning Take: Eli Lilly 4/17/25
Apr 17, 2025
This discussion highlights Eli Lilly's impressive stock surge and the increasing patient preference for oral medications over injections. The promising results of their phase three trial for an oral diabetes treatment are a key focus, emphasizing its potential for regulatory approval and market success. Additionally, the conversation navigates the effects of clinical trial outcomes on stock performance and the challenges posed by tariffs in the pharmaceutical sector, shedding light on the commitment to innovative healthcare solutions.
AI Snips
Chapters
Transcript
Episode notes
Eli Lilly's Oral Diabetes Pill Breakthrough
- Eli Lilly's oral GLP-1 pill shows injection-like efficacy for diabetes with good safety and tolerability.
- This pill could revolutionize treatment as most patients prefer pills over injections, boosting potential sales significantly.
Patients Hate Injections, Prefer Pills
- Jim Cramer shares that many patients hate injections and often discontinue treatment early.
- He personally would choose a pill immediately over injections despite their efficacy.
Stay Disciplined Amidst Volatility
- Investors should monitor pharmaceutical tariff developments impacting sales.
- Stay disciplined with investments despite recent stock volatility and clinical trial successes.